21
Participants
Start Date
October 3, 2018
Primary Completion Date
March 31, 2020
Study Completion Date
July 2, 2020
APX001
APX001
Institut Jules Bordet,Service De Microbiologie, Brussels
Hopital Erasme, Brussels
Mont-Godinne University Hospital, Yvoir
Duke University Hospital Medical Center, Durham
Augusta University (Georgia Regents University), Augusta
University of Alabama at Birmingham School of Medicine, Birmingham
University of Alabama at Birmingham (UAB), Birmingham
Infectious Diseases Unit,Sheba Medical Center, Tel Litwinsky
University of Chicago, Chicago
Washington University, St Louis
University of Texas- Health Science Center and Medical School at Houston, Houston
University of California, Davis, Davis
University of California-Davis Medical Center, Sacramento
Infectious Diseases Unit, Rambam Medical Center, Haifa
Infectious Diseases Unit, Tel Aviv
Institut Jules Bordet, Brussels
Universite Libre de Bruxelles (ULB) - Hopital Erasme, Brussels
CHU de Charleroi - Hopital Civil Marie Curie, Lodelinsart
University Hospital Mont-Godinne, Yvoir
Klinik I fur Innere Medizin- Uniklinik Koln, Cologne
University Hospital Heidelberg, Heidelberg
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - III. Medizinische Klinik Haematologie/Onkologie, Mainz
Rambam Medical Center, Haifa
Sourasky Medical Center, Tel Aviv
Sheba Medical Center, Tel Litwinsky
Hospital Universitario Mutua de Terrassa, Terrassa
Hospital General Universitario de Alicante, Alicante
Hospital VLL D Hebron, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Basilea Pharmaceutica
INDUSTRY